

Table 1: Pathology distribution

| <b>Pathology type</b>                 | <b>n</b> | <b>% of cohort<br/>(N=120)</b> | <b>Notes</b>   |
|---------------------------------------|----------|--------------------------------|--|
| Meningioma                            | 39       | 32.5%                          | 8 sphenoid wing, 5 planum/tuberculum, 2 olfactory groove                     |
| Astrocytoma                           | 30       | 25.0%                          | 11 temporal, 8 parietal, 3 frontal, 6 occipital, 1 suprasellar, 1 chiasmatic |
| Metastasis                            | 18       | 15.0%                          | Various locations  |
| Pituitary adenoma                     | 7        | 5.83%                          | Sellar/suprasellar region  |
| Vascular lesion                       | 9        | 7.5%                           | Aneurysm or AVM-related  |
| Orbital lesion                        | 8        | 6.66%                          | Intraorbital tumors  |
| Chordoma                              | 3        | 2.5%                           | Skull base   |
| Neurinoma                             | 2        | 1.6%                           | Optic nerve region   |
| Rathke's cleft cyst/Craniopharyngioma | 2        | 1.6%                           | Sellar/suprasellar   |
| Lymphoma                              | 2        | 1.6%                           | CNS involvement  |

120 patients were analyzed; 90.8% had analyzable intraoperative data; 9.2% excluded due to artifacts or documentation gaps.

Table 2: Intraoperative VEP signal quality and postoperative visual outcomes

| Signal quality category       | n  | %     | Typical intraoperative finding   | Postoperative vision (improved / unchanged / worse) |
|-------------------------------|----|-------|----------------------------------|---|
| Documentation inadequate      | 4  | 3.3%  | Missing records                  | -   |
| Artifact-dominant             | 7  | 5.8%  | Non-interpretable signal         | -   |
| Stable VEPs                   | 63 | 52.5% | Consistent amplitude and latency | 20 / 41 / 2   |
| VEP changes – badly derivable | 5  | 4.2%  | Low reproducibility              | 1 / 3 / 1   |
| VEP changes – side difference | 26 | 21.7% | Unilateral amplitude reduction   | 5 / 21 / 0  |
| VEP changes – deterioration   | 15 | 12.5% | Bilateral or progressive loss    | 2 / 8 / 5   |

Abbreviations: VEP, visual evoked potential. Percentages relative to total cohort (N=120).

Table 3: Intraoperative VEP changes and corrective interventions

| Subgroup        | n  | Common intraoperative cause                                   | Contact with visual pathway | Intervention applied | Effect on VEP signal   |
|-----------------|----|---|-----------------------------|----------------------|------------------------|
| Side difference | 26 | Manipulation near optic nerve/chiasm                          | 20/26                       | Nimodipine (11/26)   | Improved in 5/11 cases |
| Deterioration   | 15 | CUSA, bipolar coagulation, hemodynamic or temperature changes | 15/15                       | Nimodipine (10/15)   | Improved in 6/10 cases |

Deteriorations typically occurred during dural opening or early resection. In both subgroups, VEP improvement followed optimization of perfusion, irrigation, or local nimodipine use.

Table 4: Association between intraoperative VEP changes and postoperative visual outcomes

| Intraoperative VEP pattern                 | Postoperative visual deterioration (n) | Postoperative unchanged or improved (n) |
|--|--|---|
| VEP deterioration                          | 5                                      | 8                                       |
| Stable / side-difference / badly derivable | 7                                      | 92                                      |
|  |  |   |
| Diagnostic performance                     |  |   |
| Sensitivity                                | 41.7%                                  |   |
| Specificity                                | 92.0%                                  |   |

PPV: 38.5%; NPV: 92.9%.

False positives = 8; False negatives = 7.

Diagnostic metrics computed per patient using cases with analyzable intraoperative monitoring and available early ophthalmologic outcomes.